One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Tandem Diabetes Care logo
Tandem Diabetes Care TNDM
$ 16.63 -7.15%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Tandem Diabetes Care Cash Flow 2025-2011 | TNDM

Brief overview of Tandem Diabetes Care's cash flow quality

The review uses the five latest available annual reports between 2021 and 2025.

At the end of the period, operations consumed -$9.7 million rather than generating cash. This profile calls for caution.

Operating cash flow was positive in 3 of five periods. Cash generation worked overall but was not fully stable.

Operating cash flow margin dropped from 15.8% to -3.3%. Sales produced less cash per unit.

Working capital needs increased $95.9 million, or 33% of sales. This may restrain cash conversion.

Overall picture

Tandem Diabetes Care's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.

Annual Cash Flow Tandem Diabetes Care

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-9.72 M 24.2 M -31.8 M 50.5 M 111 M 24.7 M 41.9 M -8.32 M -66.1 M -61.2 M - - - - -

Depreciation & Amortization

17.7 M 16.6 M 15.7 M 14.3 M 13.8 M 10.5 M 6.07 M 5.82 M 6.87 M 5.49 M 4.83 M 4.39 M 3.17 M 2.03 M -

Accounts Payables

47.1 M 44.7 M 49.6 M 55.7 M 28 M 17.8 M 17.7 M 6.82 M 5.15 M 7.51 M 5.23 M 1.95 M - - -

Accounts Receivables

165 M 115 M 106 M 115 M 111 M 82.2 M 46.6 M 35.2 M 20.8 M 11.2 M 14.1 M 7.65 M - - -

Total Inventories

129 M 150 M 158 M 111 M 68.6 M 63.7 M 49.1 M 19.9 M 27 M 21.2 M 17.5 M 11.9 M - - -

All numbers in USD currency

Quarterly Cash Flow Tandem Diabetes Care

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -34.6 M 11.1 M 9.79 M 8.26 M -9.5 M -18.3 M 10.7 M 26.8 M -5.28 M -8 M -7.22 M 55 K -6.32 M -18.3 M 5.82 M 23.9 M 6.9 M 13.8 M 19.6 M 34.1 M 28.9 M 28.7 M 15.2 M 14.6 M -5.13 M -20.6 M 19.4 M 23 M -556 K -4.12 M 14.1 M -3.46 M -6.72 M -12.3 M -11.6 M -19 M -35.5 M - - - - - - - - - - - - -17 M - - - -8.81 M - - - - - - - -

Depreciation & Amortization

- 4.47 M 4.5 M -10.7 M 4.49 M 4.37 M 4.31 M -10.5 M 4.21 M 4.11 M 4.04 M -9.78 M 4.02 M 4.26 M 3.4 M -8.69 M 3.51 M 3.55 M 3.63 M -8.12 M 3.4 M 3.44 M 3.48 M - 2.99 M 4.04 M 1.83 M - 1.48 M 2.95 M 1.44 M -4.05 M 1.46 M 1.4 M 1.49 M -4.44 M 1.72 M 1.59 M 1.43 M -3.72 M 1.3 M 1.38 M 1.33 M -3.31 M 1.2 M 1.23 M 1.18 M -2.78 M 1.17 M 997 K 921 K - 2.46 M 1.71 M 784 K - - - - - - - -

Accounts Payables

74.8 M 64.1 M 59.9 M 47.1 M 47.5 M 55.8 M 59.8 M 44.7 M 48.8 M 47.8 M 48.1 M 49.6 M 46.1 M 57.1 M 55.2 M 55.7 M 61.5 M 50.7 M 45.3 M 28 M 27 M 27.5 M 28.2 M 17.8 M 20.5 M 16.4 M 17.8 M 17.7 M 16.3 M 9.27 M 11.2 M 6.82 M 6.2 M 3.65 M 3.75 M 5.15 M 7.6 M 6.62 M 4.89 M 7.51 M 5.61 M 6.84 M 5.97 M 5.23 M 4.02 M 4 M 4.09 M 1.95 M 3.05 M 2.52 M 2.05 M 2.35 M 2.35 M 2.35 M 2.35 M - - - - - - - -

Accounts Receivables

180 M 162 M 141 M 165 M 126 M 128 M 127 M 115 M 107 M 98.1 M 93 M 106 M 100 M 98.7 M 91.4 M 115 M 113 M 104 M 94.1 M 111 M 87.5 M 80.2 M 73.7 M 82.2 M 52.1 M 45 M 82.2 M 46.6 M 45.3 M 48.4 M 33 M 35.2 M 21.7 M 13.9 M 13 M 20.8 M 10.6 M 9.03 M 7.69 M 11.2 M 8.2 M 9.43 M 9.09 M 14.1 M 7.01 M 7.47 M 5.23 M 7.65 M 5.84 M 4.36 M 3.42 M 5.3 M 5.3 M 5.3 M 5.3 M - - - - - - - -

Total Inventories

143 M 135 M 126 M 129 M 137 M 143 M 141 M 150 M 152 M 162 M 154 M 158 M 143 M 148 M 132 M 111 M 105 M 88.1 M 80 M 68.6 M 65.7 M 66.7 M 66.8 M 63.7 M 70.6 M 62.3 M 63.7 M 49.1 M 40.7 M 27.3 M 22.8 M 19.9 M 24.4 M 24.9 M 26.5 M 27 M 30 M 25.8 M 23.7 M 21.2 M 22.9 M 21.7 M 20.2 M 17.5 M 17.6 M 14.7 M 13.6 M 11.9 M 11.9 M 11.1 M 10.2 M 10.3 M 10.3 M 10.3 M 10.3 M - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Tandem Diabetes Care, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical devices sector

Issuer Price % 24h Market Cap Country
Smith & Nephew plc Smith & Nephew plc
SNN
$ 31.16 -2.72 % $ 27 B britainBritain
Stryker Corporation Stryker Corporation
SYK
$ 325.34 -2.9 % $ 124 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 26.03 -0.83 % $ 595 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.82 5.24 % $ 38.5 M usaUSA
TransMedics Group TransMedics Group
TMDX
$ 87.58 26.96 % $ 2.98 B usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.14 1.39 % $ 356 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.45 0.03 % $ 764 M usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.09 -8.67 % $ 925 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Beyond Air Beyond Air
XAIR
$ 2.15 -1.38 % $ 17.8 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.28 -5.0 % $ 39.1 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 105.43 -1.42 % $ 20.9 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Butterfly Network Butterfly Network
BFLY
$ 6.36 5.12 % $ 1.57 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 2.88 -1.54 % $ 47 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 1.56 -3.7 % $ 4.33 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 2.92 5.8 % $ 125 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 42.83 -4.03 % $ 63.4 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.47 3.01 % $ 3.69 M usaUSA